<DOC>
	<DOCNO>NCT01828086</DOCNO>
	<brief_summary>A randomized , double-blind , placebo positive control , single multiple dose study assess safety , tolerability , pharmacokinetics pharmacodynamics CJM112 chronic plaque-type psoriasis patient .</brief_summary>
	<brief_title>Single Multiple Dose Escalation Study Assess Safety Tolerability CJM112 Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men woman 1865 year age time consent Chronic plaquetype psoriasis diagnose least 6 month time randomization At randomization , moderate severe psoriasis define : PASI score 12 great , IGA score 3 great , Body Surface Area ( BSA ) affect plaquetype psoriasis 10 % great . Female patient may include accord follow : Women childbearing potential , defined woman physiologically capable become pregnant , use highly effective method contraception dose 5 time terminal halflife study treatment . â€¢ Male subject must agree comply two highly effective contraceptive method Forms psoriasis chronic plaquetype ( incl . drug induced psoriasis ) Ongoing use prohibit psoriasis treatment prohibit medication randomization . Washout period detail protocol adhered Previous treatment IL17 IL17R block agent , include secukinumab Any live vaccine ( include nasalspray flu vaccine ) start 6 week screening , study , 24 week last dose CJM112 secukinumab Evidence active tuberculosis screen Active systemic infection ( common cold ) Pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Psoriasis , chronic plaque-type psoriasis , IL17 , monoclonal antibody</keyword>
</DOC>